Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $11.40.
Several equities research analysts have recently commented on the company. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. HC Wainwright cut their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Friday, January 10th.
Read Our Latest Stock Analysis on Reviva Pharmaceuticals
Institutional Trading of Reviva Pharmaceuticals
Reviva Pharmaceuticals Trading Down 2.3 %
RVPH stock opened at $1.25 on Friday. The company has a market capitalization of $41.80 million, a P/E ratio of -1.13 and a beta of -0.12. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.28. The business has a 50 day simple moving average of $1.79 and a 200-day simple moving average of $1.47.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
See Also
- Five stocks we like better than Reviva Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Learn Technical Analysis Skills to Master the Stock Market
- Tesla Stock: Finding a Bottom May Take Time
- The 3 Best Retail Stocks to Shop for in August
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.